Quick Answer
Crystagen is a synthetic tripeptide, Glu-Asp-Pro (EDP), from Vladimir Khavinson's bioregulator programme. The group designed it from the amino acid composition of Thymalin, a calf thymus extract, later reported it as a minor component of that extract, and assigns it to the immune system. The evidence is very thin: a patent, a few short studies of thymus and spleen tissue, mostly in rats, and computer modelling, all from one research network, with no peer-reviewed human data.
Crystagen sits in the shadow of its relatives. A PubMed search for Thymalin, the extract it was derived from, returns close to 300 records, and searches for Vilon and Thymogen, the dipeptides from the same thymus work, return roughly 80 and 100. A search for Crystagen returns one. This article sets out what is known, and it is short because the record is.
Sequence and identity
Crystagen is glutamyl-aspartyl-proline: Glu-Asp-Pro, or EDP in one-letter code. The patent that introduced it claims exactly this tripeptide, H-Glu-Asp-Pro-OH, with a molecular formula of C14H21N3O8 and a molecular weight of 359.3 [1]. Khavinson's 2020 review attaches the name Crystagen to the same sequence [2].
Origin: a component of Thymalin
Thymalin, a peptide extract of calf thymus created in 1982, was the first medicine of Khavinson's programme [2]. Because it is a mixture, the group looked for defined short peptides that could stand in for it. According to a 2021 paper from the group, the tripeptide EDP was designed and synthesised on the basis of Thymalin's amino acid composition, and ultra-high-performance liquid chromatography with mass spectrometry later confirmed it, together with Vilon (Lys-Glu), as a minor component of the extract [3]. The patent, filed in 2006 and granted in Russia in 2007 and in the United States in 2011, describes an immunogeroprotective effect, meaning protection of immune function in ageing [1].
That lineage is the whole basis for the immune assignment. It also explains a common error: Crystagen is not Thymalin. Thymalin has a clinical history of its own, covered in our Thymalin overview, and none of it can be credited to one minor component.
The proposed mechanism
Crystagen is assumed to act like the rest of the family, entering cells, reaching the nucleus and adjusting gene activity. The support for this particular peptide is limited.
- The patent reports that EDP loosened condensed chromatin in cultured lymphocytes from donors aged 75 to 88, which the inventors link to reactivation of genes silenced with age [1].
- A docking study from the group predicted that EDP, like Vilon, binds the DNA sequence AGAT [4].
- A 2023 modelling study suggested that it could fit the binding sites of the transporters LAT1, LAT2 and PEPT1, a possible route into cells [5].
Neither computer prediction has, in the papers we found, been tested experimentally for Crystagen.
What the studies show
Most of the experimental work sits in the patent. It reports increased growth of thymus and spleen explants from 24-month-old rats, protective effects on the thymus in young rats exposed to gamma radiation as a model of premature ageing, effects on mouse macrophages and on a human thymic epithelial cell line, and the chromatin changes in human lymphocytes described above [1]. It also describes an observation in 38 older people exposed to ionising radiation. Patents are not peer reviewed, and we found no journal publication of that human observation.
The single PubMed-indexed experimental paper that names Crystagen compared four short peptides in ageing spleen tissue. Crystagen was reported to activate B cells but, unlike the other three, had no effect on cell renewal [6]. The paper is in Russian, with an English translation, and its abstract does not describe the model in detail.
A 2023 organotypic culture study from the same network found that Glu-Asp-Pro increased the growth of spleen explants from both young and old rats [7].
How strong is the evidence?
- Volume. One PubMed-indexed experimental paper, a patent, a Russian-language explant study and computer modelling.
- Source. All of it comes from Khavinson's institute or close collaborators, and none of it has been replicated independently.
- Models. Explants, cultured cells and rats. Growth of tissue in a dish is an early screening signal, not evidence of better immune function in a living animal, let alone in people.
- Borrowed credibility. It is easy to let Thymalin's longer record lend weight to Crystagen. The extract's data are not the peptide's data.
The honest summary is a clearly defined molecule with a plausible origin and almost no independent biology behind it.
Where Crystagen fits
Crystagen is one of a family of short peptides that share an origin story, a proposed DNA-binding mechanism and the same evidence gaps. For that wider context, including how the thymus peptides relate to one another, see our guide to Khavinson bioregulator peptides.
References
- Khavinson VKh, et al. 2011. "Peptide substance revealing an immunogeroprotective effect, pharmaceutical composition on its base and the method of its application." US patent 8,057,810 (Russian counterpart RU 2301074, 2007). Google Patents
- Khavinson VKh. 2020. "Peptide medicines: past, present, future" (in Russian). Klinicheskaya Meditsina 98(3):165-177. doi:10.30629/0023-2149-2020-98-3-165-177
- Khavinson VKh, et al. 2021. "Identification of short peptides: optimization of target therapeutic properties of the thymus medicine" (in Russian). Molekulyarnaya Meditsina 19(3):32-37. doi:10.29296/24999490-2021-03-05
- Khavinson VK, et al. 2016. "Short Peptides Regulate Gene Expression." Bulletin of Experimental Biology and Medicine 162(2):288-292. PMID 27909961
- Khavinson VK, et al. 2023. "Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters." Biomolecules 13(3):552. PMID 36979488
- Chervyakova NA, et al. 2014. "Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process" (in Russian). Advances in Gerontology. PMID 28976144
- Chalisova NI, et al. 2023. "The stimulating effect of short peptides on cellular proliferation in organotypic tissue culture" (in Russian). Integrative Physiology 4(2):225-234. doi:10.33910/2687-1270-2023-4-2-225-234